Chapter 32. Asthma and Chronic Obstructive Pulmonary Disease
Multiple Choice
Identify the choice that best completes the statement or answers the question.
1. Prior to developing a plan for the treatment of asthma, the patient’s asthma should be
classified according to the NHLBI Expert Panel 3 guidelines. In adults mild-persistent
asthma is classifiedas asthma symptoms that occur:
1. Daily
2. Daily and limit physical activity
3. Less than twice a week
4. More than twice a week and less than once a day
2. In children age 5 to 11 years mild-persistent asthma is diagnosed when asthma symptoms occur:
1. At nighttime one to two times a month
2. At nighttime three to four times a month
3. Less than twice a week
4. Daily
3. One goal of asthma therapy outlined by the NHLBI Expert Panel 3 guidelines is:
1. Ability to use albuterol daily to control symptoms
2. Minimize exacerbations to once a month
3. Keep nighttime symptoms at a maximum of twice a week
4. Require infrequent use of beta 2 agonists (albuterol) for relief of symptoms
4. A stepwise approach to the pharmacologic management of asthma:
1. Begins with determining the severity of asthma and assessing asthma control
2. Is used when asthma is severe and requires daily steroids
3. Allows for each provider to determine their personal approach to the care of
asthmatic patients
4. Provides a framework for the management of severe asthmatics, but is not as
helpful when patients have intermittent asthma
5. Treatment for mild intermittent asthma is:
1. Daily inhaled medium-dose corticosteroids
2. Short-acting beta-2-agonists (albuterol) as needed
3. Long-acting beta-2-agonists every morning as a preventative
4. Montelukast (Singulair) daily
6. The first-line therapy for mild-persistent asthma is:
1. High-dose montelukast
2. Theophylline
3. Low-dose inhaled corticosteroids
4. Long-acting beta-2-agonists
7. Monitoring a patient with persistent asthma includes:
1. Monitoring how frequently the patient has an upper respiratory infection (URI)
during treatment
, 2. Monthly in-office spirometry testing
3. Determining if the patient has increased use of his or her long-acting
beta-2-agonist due to exacerbations
4. Evaluating the patient every 1 to 6 months to determine if the patient needs to step
up or down in their therapy
8. Asthma exacerbations at home are managed by the patient by:
1. Increasing frequency of beta-2-agonists and contacting their provider
2. Doubling inhaled corticosteroid doses
3. Increasing frequency of beta-2-agonists
4. Starting montelukast (Singulair)
9. Patients who are at risk of a fatal asthma attack include patients:
1. With moderate persistent asthma
2. With a history of requiring intubation or ICU admission for asthma
3. Who are on daily inhaled corticosteroid therapy
4. Who are pregnant
10. Pregnant patients with asthma may safely use throughout their pregnancy.
1. Oral terbutaline
2. Prednisone
3. Inhaled corticosteroids (budesonide)
4. Montelukast (Singulair)
11. One goal of asthma management in children is:
1. They independently manage their asthma
2. Participation in school and sports activities
3. No exacerbations
4. Minimal use of inhaled corticosteroids
12. Medications used in the management of patients with chronic obstructive pulmonary disease
(COPD) include:
1. Inhaled beta-2-agonists
2. Inhaled anticholinergics (ipratropium)
3. Inhaled corticosteroids
4. All of the above
13. Patients with a COPD exacerbation may require:
1. Doubling of inhaled corticosteroid dose
2. Systemic corticosteroid burst
3. Continuous inhaled beta-2-agonists
4. Leukotriene therapy
14. Patients with COPD require monitoring of:
1. Beta-2-agonist use
2. Serum electrolytes
3. Blood pressure
4. Neuropsychiatric effects of montelukast
Multiple Choice
Identify the choice that best completes the statement or answers the question.
1. Prior to developing a plan for the treatment of asthma, the patient’s asthma should be
classified according to the NHLBI Expert Panel 3 guidelines. In adults mild-persistent
asthma is classifiedas asthma symptoms that occur:
1. Daily
2. Daily and limit physical activity
3. Less than twice a week
4. More than twice a week and less than once a day
2. In children age 5 to 11 years mild-persistent asthma is diagnosed when asthma symptoms occur:
1. At nighttime one to two times a month
2. At nighttime three to four times a month
3. Less than twice a week
4. Daily
3. One goal of asthma therapy outlined by the NHLBI Expert Panel 3 guidelines is:
1. Ability to use albuterol daily to control symptoms
2. Minimize exacerbations to once a month
3. Keep nighttime symptoms at a maximum of twice a week
4. Require infrequent use of beta 2 agonists (albuterol) for relief of symptoms
4. A stepwise approach to the pharmacologic management of asthma:
1. Begins with determining the severity of asthma and assessing asthma control
2. Is used when asthma is severe and requires daily steroids
3. Allows for each provider to determine their personal approach to the care of
asthmatic patients
4. Provides a framework for the management of severe asthmatics, but is not as
helpful when patients have intermittent asthma
5. Treatment for mild intermittent asthma is:
1. Daily inhaled medium-dose corticosteroids
2. Short-acting beta-2-agonists (albuterol) as needed
3. Long-acting beta-2-agonists every morning as a preventative
4. Montelukast (Singulair) daily
6. The first-line therapy for mild-persistent asthma is:
1. High-dose montelukast
2. Theophylline
3. Low-dose inhaled corticosteroids
4. Long-acting beta-2-agonists
7. Monitoring a patient with persistent asthma includes:
1. Monitoring how frequently the patient has an upper respiratory infection (URI)
during treatment
, 2. Monthly in-office spirometry testing
3. Determining if the patient has increased use of his or her long-acting
beta-2-agonist due to exacerbations
4. Evaluating the patient every 1 to 6 months to determine if the patient needs to step
up or down in their therapy
8. Asthma exacerbations at home are managed by the patient by:
1. Increasing frequency of beta-2-agonists and contacting their provider
2. Doubling inhaled corticosteroid doses
3. Increasing frequency of beta-2-agonists
4. Starting montelukast (Singulair)
9. Patients who are at risk of a fatal asthma attack include patients:
1. With moderate persistent asthma
2. With a history of requiring intubation or ICU admission for asthma
3. Who are on daily inhaled corticosteroid therapy
4. Who are pregnant
10. Pregnant patients with asthma may safely use throughout their pregnancy.
1. Oral terbutaline
2. Prednisone
3. Inhaled corticosteroids (budesonide)
4. Montelukast (Singulair)
11. One goal of asthma management in children is:
1. They independently manage their asthma
2. Participation in school and sports activities
3. No exacerbations
4. Minimal use of inhaled corticosteroids
12. Medications used in the management of patients with chronic obstructive pulmonary disease
(COPD) include:
1. Inhaled beta-2-agonists
2. Inhaled anticholinergics (ipratropium)
3. Inhaled corticosteroids
4. All of the above
13. Patients with a COPD exacerbation may require:
1. Doubling of inhaled corticosteroid dose
2. Systemic corticosteroid burst
3. Continuous inhaled beta-2-agonists
4. Leukotriene therapy
14. Patients with COPD require monitoring of:
1. Beta-2-agonist use
2. Serum electrolytes
3. Blood pressure
4. Neuropsychiatric effects of montelukast
